MDMA Identifies Top FDA, HCFA Priorities In 2001 Public Policy Agenda
This article was originally published in The Gray Sheet
Executive Summary
The Medical Device Manufacturers Association's 2001 public policy agenda spotlights the debate over the claims substantiation guidance, which is expected to be released this year.
You may also be interested in...
AdvaMed Offers HCFA Criteria For New "Pass-Through" Device Categories
A device that is at least 20% more costly than similar predicate devices should warrant a new "pass-through" category under HCFA's hospital outpatient prospective payment system (OPPS), according to AdvaMed.
PTCA Catheter Downclassification Carries Unresolved Safety Issues - Panel
Postmarket surveillance requirements should be part of any decision to downclassify percutaneous transluminal coronary angioplasty (PTCA) balloon catheters from Class III to Class II, according to FDA's Circulatory System Devices Panel.
Device Industry Growth Signals FDA Inspection Woes - Performance Plan
The inspection rate of once every 3.3 years for high-risk device makers achieved by FDA in FY 1999 stands to erode further, barring additional future funding, the agency acknowledges in its December "Performance Plan Summary" submitted to Congress.